TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23620091

Group type: EXPERIMENTAL
Intervention: Postoperative best-corrected visual acuity (BCVA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Preoperative junction line integrity between inner and outer segments of photoreceptors (IS/OS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Postoperative VA
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Foveal thickness
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Postoperative outer retinal layer integrity
Number of subjects: 23
Study: 23620192

Group type: EXPERIMENTAL
Intervention: Children who screened positive for PTSD
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Children whose mothers had PTSD
Number of subjects: 167

Group type: COMPARATOR
Intervention: Children who did not screen positive for PTSD
Number of subjects: 167
Study: 23620304

Group type: EXPERIMENTAL
Intervention: Excess Skin (ES)
Number of subjects: 26
Study: 23620574

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Cytogenetic response
Number of subjects: 483
Study: 23620742

Group type: EXPERIMENTAL
Intervention: Laser Doppler Flowmetry (LDF)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging (LSCI)
Number of subjects: 15
Study: 23621514

Group type: EXPERIMENTAL
Intervention: SNS01 (Ectoin Rhinitis nasal spray)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BNO-101 (Sinupret forte dragées)
Number of subjects: 0
Study: 23622855

Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Attention-Deficit/Hyperactivity Disorder (ADHD)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Typically Developing Controls (TDC)
Number of subjects: 109
Study: 23622977

Group type: EXPERIMENTAL
Intervention: Ballooned-tip PEGJ feeding tubes
Number of subjects: 7
Study: 23623397

Group type: EXPERIMENTAL
Intervention: Eculizumab 600 mg intravenous weekly for 4 weeks, 900 mg in the fifth week, and then 900 mg every 2 weeks for 48 weeks.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Eculizumab withdrawal
Number of subjects: 14
Study: 23623559

Group type: EXPERIMENTAL
Intervention: Sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood cells
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional chromosome banding (CCB) analysis of bone marrow metaphases
Number of subjects: 360
Study: 23624172

Group type: EXPERIMENTAL
Intervention: Active weight gain prevention intervention
Number of subjects: 272

Group type: COMPARATOR
Intervention: Alternative intervention focused on oral health
Number of subjects: 272
Study: 23624209

Group type: EXPERIMENTAL
Intervention: CD30 positive cases after chemotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: CD30 negative cases after chemotherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: After first line treatment in CD30 positive cases
Number of subjects: 49

Group type: COMPARATOR
Intervention: After first line treatment in CD30 negative cases
Number of subjects: 49
Study: 23624851

Group type: EXPERIMENTAL
Intervention: Ad5 [E1-, E2b-]-CEA(6D)
Number of subjects: 0
Study: 23624993

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6, 1.2, or 1.8 mg daily for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (daily for 12 weeks)
Number of subjects: 40
Study: 23625112

Group type: EXPERIMENTAL
Intervention: SBP of 135-139 mmHg and DBP of 74-76 mmHg
Number of subjects: 34009

Group type: EXPERIMENTAL
Intervention: SBP of 142-150 mmHg and DBP of 78-79 mmHg
Number of subjects: 34009

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 34009
Study: 23625132

Group type: EXPERIMENTAL
Intervention: VolumeView™-CCO method
Number of subjects: 72

Group type: COMPARATOR
Intervention: PiCCO2™-CCO pulse wave analysis
Number of subjects: 72
Study: 23626752

Group type: EXPERIMENTAL
Intervention: Moxifloxacin treatment
Number of subjects: 3909
Study: 23626901

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) therapy (0.033 mg/kg daily for 4 weeks)
Number of subjects: 205
Study: 23627193

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 226
Study: 23627666

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study: 23627920

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 155
Study: 23628375

Group type: EXPERIMENTAL
Intervention: Catch-up growth
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) use
Number of subjects: 483

Group type: COMPARATOR
Intervention: Normal height (NH) group
Number of subjects: 483
Study: 23629519

Group type: EXPERIMENTAL
Intervention: Self-reported CRC screening behavior (colonoscopy, sigmoidoscopy, fecal occult blood testing)
Number of subjects: 2138

Group type: EXPERIMENTAL
Intervention: Fully adjusted model for CRC screening
Number of subjects: 2138

Group type: EXPERIMENTAL
Intervention: Usual source of care
Number of subjects: 2138
Study: 23629714

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZI) 500 mg once a day for 3 days
Number of subjects: 12
Study: 23629822

Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitors (statins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 23630200

Group type: EXPERIMENTAL
Intervention: Cediranib (30 mg once daily in 28-day cycles)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cediranib
Number of subjects: 46
Study: 23630218

Group type: EXPERIMENTAL
Intervention: Integrated electronic systems for real-time data collection
Number of subjects: 44
Study: 23631460

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control (anesthetic agents only)
Number of subjects: 166
Study: 23631814

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation management in 2010 (including increased use of noninvasive positive-pressure ventilation, decreased tidal volume, and increased positive end-expiratory pressure)
Number of subjects: 18302

Group type: EXPERIMENTAL
Intervention: Adjusted mechanical ventilation management in 2010
Number of subjects: 18302
Study: 23632474

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg once daily plus intravenous paclitaxel 80 mg m(-2) on days 1, 8, and 15 of each 28-day cycle
Number of subjects: 102
Study: 23632636

Group type: EXPERIMENTAL
Intervention: Palmitic acid (PA) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNFα treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PA and TNFα treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockdown of EGR-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Term placenta from obese women
Number of subjects: 0
Study: 23632904

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.03-0.06 mg/kg/day) for >12 months (mean duration 4.1 years)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 41
Study: 23633099

Group type: EXPERIMENTAL
Intervention: Standard-dose 3F8 (SD-3F8) (20 mg/m2 daily for 5 days per cycle)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: High-dose 3F8 (HD-3F8) (80 mg/m2 daily for 5 days per cycle)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Prior brain irradiation (external-beam radiotherapy)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Overall anti-GD2 MoAb immunotherapy
Number of subjects: 215
Study: 23633215

Group type: EXPERIMENTAL
Intervention: STN-DBS (Stim-ON)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: STN-DBS (Stim-OFF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study: 23633404

Group type: EXPERIMENTAL
Intervention: H5 DNA prime followed by H5N1 monovalent inactivated vaccine boost at intervals of 4, 8, 12, 16, or 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 doses of H5N1 monovalent inactivated vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H5 DNA prime followed by H5N1 monovalent inactivated vaccine boost at intervals of ≥12 weeks
Number of subjects: 0
Study: 23633657

Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes with progression
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes without progression
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy eyes
Number of subjects: 62
Study: 23633663

Group type: EXPERIMENTAL
Intervention: cSLO FAF imaging
Number of subjects: 22
Study: 23634291

Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, and bevacizumab
Number of subjects: 38
Study: 23635417

Group type: EXPERIMENTAL
Intervention: Decide2Quit.org (Google-referred smokers)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Google smokers
Number of subjects: 605

Group type: COMPARATOR
Intervention: Medical-referred smokers
Number of subjects: 605

Group type: COMPARATOR
Intervention: Dental-referred smokers
Number of subjects: 605
Study: 23635743

Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing of maternal plasma DNA
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for trisomy 21 (T21)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for trisomy 18 (T18)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for trisomy 13 (T13)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for monosomy X
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing for whole chromosome aneuploidy
Number of subjects: 113
Study: 23635746

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation
Number of subjects: 135
Study: 23636237

Group type: EXPERIMENTAL
Intervention: Variant rs838145
Number of subjects: 71393

Group type: EXPERIMENTAL
Intervention: Variant rs1421085 (FTO)
Number of subjects: 71393
Study: 23636240

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: FADS SNP rs1535 (homozygous carriers of the minor allele)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: FADS SNP rs174448 (minor allele carriers)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: FADS SNP rs174575 (minor allele carriers)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Fish intake at 3 years
Number of subjects: 409
Study: 23636448

Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg plus ketoconazole 400 mg once daily for 5 days after 7 days of pazopanib 400 mg alone.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg plus esomeprazole 40 mg once daily for 5 days after 7 days of pazopanib 800 mg alone.
Number of subjects: 34
Study: 23636603

Group type: EXPERIMENTAL
Intervention: Facilitators of CPR training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Barriers to taking CPR training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Facilitators of providing CPR
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Barriers to providing CPR
Number of subjects: 24
Study: 23636645

Group type: EXPERIMENTAL
Intervention: Paxman PSC-2 machine (PAX)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Cold cap (CC)
Number of subjects: 238

Group type: COMPARATOR
Intervention: No cooling
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Cooling (PAX and CC combined)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: PAX and CC
Number of subjects: 238
Study: 23636668

Group type: EXPERIMENTAL
Intervention: Elevated hemolysis (LDH levels ≥1.5 times the upper limit of normal)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Combination of LDH ≥1.5 × ULN with clinical symptoms (abdominal pain, chest pain, dyspnea, hemoglobinuria)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: TE occurrence
Number of subjects: 301
Study: 23636870

Group type: EXPERIMENTAL
Intervention: Amigo™ remote catheter system
Number of subjects: 181
Study: 23637029

Group type: EXPERIMENTAL
Intervention: LAP-BAND System
Number of subjects: 149
Study: 23637051

Group type: EXPERIMENTAL
Intervention: Deferasirox taken with soft food at breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferasirox taken as per label (empty stomach with water, apple juice, or orange juice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferasirox administration modes during assessment phase
Number of subjects: 0
Study: 23638111

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) training
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (no SDM training)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Experimental group (with SDM training)
Number of subjects: 244
Study: 23638197

Group type: EXPERIMENTAL
Intervention: Chagas heart disease
Number of subjects: 342

Group type: COMPARATOR
Intervention: Non-Chagas cardiomyopathy
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Amiodarone use
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Beta-blocker use
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: LVEDD
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Creatinine clearance
Number of subjects: 342
Study: 23638448

Group type: EXPERIMENTAL
Intervention: Terazosin, flexible dose 1 to 6 mg/d
Number of subjects: 23
Study: 23639146

Group type: COMPARATOR
Intervention: OROS methylphenidate (extended-release), robust dosing, duration up to 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ADHD comparison group
Number of subjects: 0
Study: 23639189

Group type: EXPERIMENTAL
Intervention: Hydroethanolic extract of Lippia alba leaves
Number of subjects: 21
Study: 23639498

Group type: EXPERIMENTAL
Intervention: Consent obtained on the day of surgery
Number of subjects: 2

Group type: COMPARATOR
Intervention: Consent obtained before the day of surgery
Number of subjects: 2
Study: 23640206

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 28
Study: 23640671

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 385

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 385
Study: 23641946

Group type: EXPERIMENTAL
Intervention: Diaphragm function assessed by twitch tracheal pressure in response to bilateral anterior magnetic phrenic nerve stimulation (Ptr,stim) on Day 1
Number of subjects: 85

Group type: COMPARATOR
Intervention: Diaphragm function on Day 1 in ICU survivors
Number of subjects: 85

Group type: COMPARATOR
Intervention: Diaphragm function on Day 1 in ICU nonsurvivors
Number of subjects: 85

Group type: COMPARATOR
Intervention: Diaphragm function on Day 1 in hospital survivors
Number of subjects: 85

Group type: COMPARATOR
Intervention: Diaphragm function on Day 1 in hospital nonsurvivors
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Independent predictors of low Ptr,stim
Number of subjects: 85
Study: 23642342

Group type: EXPERIMENTAL
Intervention: Long-term implanted seizure advisory system
Number of subjects: 15
Study: 23642526

Group type: EXPERIMENTAL
Intervention: FEC (5-fluorouracil 600 mg/m(2), epirubicin 90 mg/m(2), cyclophosphamide 600 mg/m(2)) followed by weekly paclitaxel (80 mg/m(2)) with bevacizumab 10 mg/kg every 2 weeks
Number of subjects: 56
Study: 23642625

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with paclitaxel 135 mg/m(2) and carboplatin AUC 5 every 3 weeks for 3 cycles
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with paclitaxel/carboplatin
Number of subjects: 71
Study: 23642924

Group type: EXPERIMENTAL
Intervention: Protégé EverFlex Self-Expanding Peripheral Stent System
Number of subjects: 287
Study: 23643429

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23643486

Group type: EXPERIMENTAL
Intervention: Extrafe beclometasone (first ICS)
Number of subjects: 30354

Group type: EXPERIMENTAL
Intervention: Extrafe beclometasone (switched from another ICS)
Number of subjects: 30354
Study: 23643560

Group type: EXPERIMENTAL
Intervention: Physician-modified endovascular graft (PMEG)
Number of subjects: 26
Study: 23643591

Group type: EXPERIMENTAL
Intervention: Continued smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smoking
Number of subjects: 0
Study: 23643595

Group type: EXPERIMENTAL
Intervention: Copeptin levels <14 pmol/L combined with cardiac troponin I (cTnI) <99th percentile
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: Copeptin >14 pmol/L
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: Combination of copeptin and cTnI
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: Abnormal copeptin and cTnI
Number of subjects: 1967
Study: 23644082

Group type: EXPERIMENTAL
Intervention: Transcatheter valve therapy (TVT) devices
Number of subjects: 0
Study: 23644181

Group type: EXPERIMENTAL
Intervention: Average absolute Ecc-mid lower than -16.9%
Number of subjects: 1768

Group type: EXPERIMENTAL
Intervention: Ecc-mid
Number of subjects: 1768

Group type: EXPERIMENTAL
Intervention: Ecc-mid added to risk factors, LV ejection fraction, and LV mass index
Number of subjects: 1768

Group type: EXPERIMENTAL
Intervention: Circumferential strain
Number of subjects: 1768
Study: 23644386

Group type: EXPERIMENTAL
Intervention: (90)Y radioembolization
Number of subjects: 56

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 56
Study: 23645402

Group type: EXPERIMENTAL
Intervention: Profiles of exhaled volatile organic compounds (VOCs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Baseline values of patients with exacerbation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide fraction (FeNO) and lung function
Number of subjects: 40
Study: 23645591

Group type: EXPERIMENTAL
Intervention: Continued treatment with MAPK inhibitors (BRAF and MEK inhibitors) after disease progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAPK inhibitors (dabrafenib, trametinib, or combination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term melanoma cultures from resistant tumor biopsies treated with MAPK inhibitors
Number of subjects: 0
Study: 23645694

Group type: EXPERIMENTAL
Intervention: escalated dose subcutaneous alemtuzumab (starting at 30 mg three times per week, escalating to 90 mg weekly) with rituximab (375 mg/m² weekly)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: escalated dose subcutaneous alemtuzumab with rituximab
Number of subjects: 28
Study: 23645911

Group type: EXPERIMENTAL
Intervention: Presentation of a question prompt sheet to increase patient involvement during consultation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 23646035

Group type: EXPERIMENTAL
Intervention: Mobile phone mood ratings
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paper-and-pencil mood ratings
Number of subjects: 40
Study: 23646111

Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy (Caucasian ethnicity)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy (Black ethnicity)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy (Caucasian ethnicity, demographically adjusted)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy (Black ethnicity, demographically adjusted)
Number of subjects: 587
Study: 23647568

Group type: EXPERIMENTAL
Intervention: SBP 180-load
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SBP variability
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Maximum BP increases from baseline and SBP and MAP loads
Number of subjects: 117
Study: 23647688

Group type: EXPERIMENTAL
Intervention: Sustained-release acetaminophen
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Glucosamine
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Medication factors (side effects, out-of-pocket costs, mode of action, treatment schedule)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Patient characteristics
Number of subjects: 188
Study: 23647704

Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Number of subjects: 150
Study: 23647796

Group type: EXPERIMENTAL
Intervention: SFA occlusion
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Collateral vessels (0 to 3 collaterals)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Collateral vessels (4 to 7 collaterals)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Collateral vessels (≥8 collaterals)
Number of subjects: 457
Study: 23648011

Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 2017
Study: 23650556

Group type: EXPERIMENTAL
Intervention: DHEAS
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Baseline cortisol
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Stimulated cortisol
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Basal cortisol
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Delta cortisol
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Cortisol/DHEA ratio
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Cortisol/DHEAS ratio
Number of subjects: 231
Study: 23651760

Group type: EXPERIMENTAL
Intervention: In-hospital delirium
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: In-hospital delirium (but free of delirium at follow-up)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Few or no signs of depression at follow-up
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Inattention
Number of subjects: 53
Study: 23652269

Group type: EXPERIMENTAL
Intervention: Dalfampridine (0.5-2.0 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 23652845

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced angiographic sequences
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Unenhanced angiographic sequences
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Perfusion sequences
Number of subjects: 274
Study: 23656846

Group type: EXPERIMENTAL
Intervention: Lifetime Axis I unipolar mood or anxiety diagnosis
Number of subjects: 121

Group type: COMPARATOR
Intervention: No lifetime Axis I unipolar mood or anxiety diagnosis
Number of subjects: 121